Works matching AU Chen, Horng H.
Results: 44
Dopamine vs nesiritide for acute heart failure with renal dysfunction--reply.
- Published in:
- 2014
- By:
- Publication type:
- commentary
Dopamine vs Nesiritide for Acute Heart Failure With Renal Dysfunction.
- Published in:
- 2014
- By:
- Publication type:
- Letter to the Editor
Low-dose dopamine or low-dose nesiritide in acute heart failure with renal dysfunction: the ROSE acute heart failure randomized trial.
- Published in:
- 2013
- By:
- Publication type:
- journal article
Low-Dose Dopamine or Low-Dose Nesiritide in Acute Heart Failure With Renal Dysfunction.
- Published in:
- JAMA: Journal of the American Medical Association, 2013, v. 310, n. 23, p. 2533, doi. 10.1001/jama.2013.282190
- By:
- Publication type:
- Article
Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial.
- Published in:
- 2013
- By:
- Publication type:
- journal article
Effect of Phosphodiesterase-5 Inhibition on Exercise Capacity and Clinical Status in Heart Failure With Preserved Ejection Fraction.
- Published in:
- JAMA: Journal of the American Medical Association, 2013, v. 309, n. 12, p. 1268, doi. 10.1001/jama.2013.2024
- By:
- Publication type:
- Article
Acute oral pegylated human BNP activates cGMP and decreases mean arterial pressure in normal dogs
- Published in:
- 2005
- By:
- Publication type:
- Abstract
BNP enhances renal actions of lasix and suppresses lasix-induced aldosterone activation in experimental heart failure
- Published in:
- 2003
- By:
- Publication type:
- Abstract
Effects of phosphodiesterase V inhibition alone and in combination with BNP on cardiovascular and renal response to volume load in human preclinical diastolic dysfunction.
- Published in:
- Physiological Reports, 2021, v. 9, n. 16, p. 1, doi. 10.14814/phy2.14974
- By:
- Publication type:
- Article
Natriuretic peptide pathways in heart failure: further therapeutic possibilities.
- Published in:
- Cardiovascular Research, 2022, v. 118, n. 18, p. 3416, doi. 10.1093/cvr/cvac125
- By:
- Publication type:
- Article
B-type natriuretic peptide and extracellular matrix protein interactions in human cardiac fibroblasts.
- Published in:
- Journal of Cellular Physiology, 2010, v. 225, n. 1, p. 251, doi. 10.1002/jcp.22253
- By:
- Publication type:
- Article
Natriuretic peptide levels and predicting risk of developing new diabetes mellitus and metabolic syndrome.
- Published in:
- Diabetes, Obesity & Metabolism, 2025, v. 27, n. 2, p. 777, doi. 10.1111/dom.16073
- By:
- Publication type:
- Article
The role of multimodality imaging in diabetic cardiomyopathy: a brief review.
- Published in:
- Frontiers in Endocrinology, 2025, p. 1, doi. 10.3389/fendo.2024.1405031
- By:
- Publication type:
- Article
Renal actions of synthetic Dendroaspis natriuretic peptide.
- Published in:
- Kidney International, 1999, v. 56, n. 2, p. 502, doi. 10.1046/j.1523-1755.1999.00573.x
- By:
- Publication type:
- Article
Implications of peripheral oedema in heart failure with preserved ejection fraction: a heart failure network analysis.
- Published in:
- ESC Heart Failure, 2021, v. 8, n. 1, p. 662, doi. 10.1002/ehf2.13159
- By:
- Publication type:
- Article
The Importance of Natriuretic Peptides in Cardiometabolic Diseases.
- Published in:
- Journal of the Endocrine Society, 2020, v. 4, n. 6, p. 1, doi. 10.1210/jendso/bvaa052
- By:
- Publication type:
- Article
Effect of Inorganic Nitrite vs Placebo on Exercise Capacity Among Patients With Heart Failure With Preserved Ejection Fraction: The INDIE-HFpEF Randomized Clinical Trial.
- Published in:
- 2018
- By:
- Publication type:
- journal article
Pharmacodynamics of a Novel Designer Natriuretic Peptide, CD-NP, in a First-in-Human Clinical Trial in Healthy Subjects.
- Published in:
- Journal of Clinical Pharmacology, 2010, v. 50, n. 6, p. 668, doi. 10.1177/0091270009336233
- By:
- Publication type:
- Article
Pharmacodynamics of a Novel Designer Natriuretic Peptide, CD-NP, in a First-in-Human Clinical Trial in Healthy Subjects.
- Published in:
- Journal of Clinical Pharmacology, 2009, v. 49, n. 6, p. 668, doi. 10.1177/0091270009336233
- By:
- Publication type:
- Article
Biomarker-based risk prediction in the community.
- Published in:
- European Journal of Heart Failure. Supplements, 2016, v. 18, n. 11, p. 1342, doi. 10.1002/ejhf.663
- By:
- Publication type:
- Article
Effect of cardiac resynchronization therapy on broad neurohormone biomarkers in heart failure.
- Published in:
- Journal of Interventional Cardiac Electrophysiology, 2011, v. 30, n. 3, p. 241, doi. 10.1007/s10840-011-9551-7
- By:
- Publication type:
- Article
Suppression of Tumorigenicity 2 in Heart Failure With Preserved Ejection Fraction.
- Published in:
- 2017
- By:
- Publication type:
- journal article
M-atrial natriuretic peptide and nitroglycerin in a canine model of experimental acute hypertensive heart failure: differential actions of 2 cGMP activating therapeutics.
- Published in:
- 2014
- By:
- Publication type:
- journal article
Evidence for Angiotensin II as a Naturally Existing Suppressor for the Guanylyl Cyclase A Receptor and Cyclic GMP Generation.
- Published in:
- International Journal of Molecular Sciences, 2023, v. 24, n. 10, p. 8547, doi. 10.3390/ijms24108547
- By:
- Publication type:
- Article
Cardiac resynchronization therapy improves myocardial conduction.
- Published in:
- Pacing & Clinical Electrophysiology, 2019, v. 42, n. 2, p. 238, doi. 10.1111/pace.13581
- By:
- Publication type:
- Article
Cenderitide, a novel dual GC-A and GC-B receptor activator, is a potent chronic cardiorenal fibroinhibiting peptide which suppresses aldosterone and reduces proteinuria in models of ardiorenal fibrosis.
- Published in:
- 2011
- By:
- Publication type:
- Abstract
Treatment with CBA-NP a novel chimeric natriuretic peptide attenuates cardiorenal fibrosis and improves diastolic dysfunction in diabetic rat model.
- Published in:
- 2011
- By:
- Publication type:
- Abstract
Cenderitide (CD-NP), a novel peptide designed to activate both guanylyl cyclase B and A, activates the second messenger cGMP, suppresses aldosterone, and preserves GFR without reducing blood pressure in a proof-of-concept study in patients with chronic heart failure
- Published in:
- 2011
- By:
- Publication type:
- Abstract
Incidence of Preclinical Heart Failure in a Community Population.
- Published in:
- 2022
- By:
- Publication type:
- journal article
Cardiorenal Effects of Long-Term Phosphodiesterase V Inhibition in Pre-Heart Failure.
- Published in:
- 2022
- By:
- Publication type:
- journal article
Assessing intrinsic renal sodium avidity in acute heart failure: implications in predicting and guiding decongestion.
- Published in:
- European Journal of Heart Failure, 2022, v. 24, n. 10, p. 1978, doi. 10.1002/ejhf.2662
- By:
- Publication type:
- Article
Biomarker-based risk prediction in the community.
- Published in:
- 2016
- By:
- Publication type:
- journal article
Chronic subcutaneous brain natriuretic peptide therapy in asymptomatic systolic heart failure.
- Published in:
- 2016
- By:
- Publication type:
- journal article
Intact acute cardiorenal and humoral responsiveness following chronic subcutaneous administration of the cardiac peptide BNP in experimental heart failure
- Published in:
- European Journal of Heart Failure, 2006, v. 8, n. 7, p. 681, doi. 10.1016/j.ejheart.2005.12.005
- By:
- Publication type:
- Article
Leukemia inhibitory factor is augmented in the heart in experimental heart failure
- Published in:
- 2003
- By:
- Publication type:
- journal article
The modulating actions of sulfonylurea on atrial natriuretic peptide release in experimental acute heart failure.
- Published in:
- 2000
- By:
- Publication type:
- journal article
M-atrial natriuretic peptide and nitroglycerin in experimental acute hypertensive heart failure: differential actions of two cGMP activating therapeutics.
- Published in:
- 2013
- By:
- Publication type:
- Abstract
Chronic natriuretic peptide protein therapeutics.
- Published in:
- 2013
- By:
- Publication type:
- Abstract
Insulin Therapy is Associated With Increased Myocardial Interstitial Fibrosis and Cardiomyocyte Apoptosis in a Rodent Model of Experimental Diabetes.
- Published in:
- Frontiers in Physiology, 2022, v. 13, p. 1, doi. 10.3389/fphys.2022.890907
- By:
- Publication type:
- Article
Cell Surface Protein Disulfide Isomerase Regulates Natriuretic Peptide Generation of Cyclic Guanosine Monophosphate.
- Published in:
- PLoS ONE, 2014, v. 9, n. 11, p. 1, doi. 10.1371/journal.pone.0112986
- By:
- Publication type:
- Article
Cenderitide-Eluting Film for Potential Cardiac Patch Applications.
- Published in:
- PLoS ONE, 2013, v. 8, n. 7, p. 1, doi. 10.1371/journal.pone.0068346
- By:
- Publication type:
- Article
In-Vivo Evaluation of an In Situ Polymer Precipitation Delivery System for a Novel Natriuretic Peptide.
- Published in:
- PLoS ONE, 2013, v. 8, n. 2, p. 1, doi. 10.1371/journal.pone.0052484
- By:
- Publication type:
- Article
CD-NP: A Novel Engineered Dual Guanylyl Cyclase Activator with Anti-Fibrotic Actions in the Heart.
- Published in:
- PLoS ONE, 2012, v. 7, n. 12, p. 1, doi. 10.1371/journal.pone.0052422
- By:
- Publication type:
- Article
A Human Study to Evaluate Safety, Tolerability, and Cyclic GMP Activating Properties of Cenderitide in Subjects With Stable Chronic Heart Failure.
- Published in:
- Clinical Pharmacology & Therapeutics, 2018, v. 104, n. 3, p. 546, doi. 10.1002/cpt.974
- By:
- Publication type:
- Article